Fast‑moving regulation demands clear, compliant storytelling. Ground campaigns in approved labelling and use the FDA’s newly published CRLs to pre‑empt pitfalls and sharpen claims—across every channel. Read ICON’s lat...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Rediscovering HIV: A new decade of research and innovation on the horizon
Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
What clinical holds and pauses mean for COVID-19 countermeasure timelines
ICON’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile COVID-19 trials are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards. Read more in this Biocentury article.
-
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
-
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
Here’s what we have to do to show a coronavirus vaccine works
A article featuring expert commentary from ICON's Cynthia Dukes about the development of a vaccine for COVID-19.
-
Coronavirus vaccine: how pharma is picking up the pace
A PharmaPhorum article featuring commentary from ICON's Dr. Nuala Murphy and Dr. James Cummings.
-
COVID-19 will spur decentralised and hybrid trials – Novartis hails digital investment
An article featuring commentary from Dr. Nuala Murphy regarding the use of decentralised and hybrid trials during the COVID-19 crisis.
-
COVID-19 vaccine response
James Cummings, President, ICON Government & Public Health Solutions, and Beth Tulip, Vice President, Project Management, Vaccines & Infectious Diseases, discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine.
-
ICON launches Coronavirus Observatory
This article discusses ICON’s Coronavirus Observatory, a tool providing real-time updates on COVID-19 vaccine trials, and insights into key issues.
Read more about ICON's expertise in COVID-19 clinical trials.
